CME

This activity is supported by an educational grant from Bristol-Myers Squibb.

Immune Checkpoint Inhibitors in Advanced Melanoma: What You May Have Missed in Madrid

Immune Checkpoint Inhibitors in Advanced Melanoma: What You May Have Missed in Madrid

This activity is supported by an educational grant from Bristol-Myers Squibb.

Overview

Author(s)/Faculty: Axel Hauschild, MD; Jeffrey S. Weber, MD, PhD
Source: Healio - Hematology/Oncology Education Lab
Type: VideoArticles/Items: 3
Release Date: 12/1/2017Expiration Date: 11/30/2018
Credit Type: CMENumber of Credits: 1
Cost: FreeProvider: Vindico Medical Education
The incidence of melanoma in the United States continues to rise as demonstrated by the Surveillance, Epidemiology and End Results (SEER) data, which shows a 60% increase in the incidence of melanoma in Caucasians over the past 30 years. In patients whose melanoma is detected early, 5-year survival rates are estimated at about 98%, but for those with advanced disease, these rates drop dramatically. The approval and integration of immune checkpoint inhibitors into treatment algorithms for advanced melanoma have demonstrated significant durations of response and survival outcomes as seen by long-term analysis of pivotal clinical studies. Furthermore, the continued evaluation of immune checkpoint inhibitors in novel indications, or in novel combinations, have the potential to further enhance clinical outcomes for patients with advanced melanoma. In this CME activity, Dr. Axel Hauschild and Dr. Jeffrey S. Weber will discuss and evaluate clinical studies presented at recent scientific meetings pertaining to the utilization of immune checkpoint inhibitors in the treatment of advanced melanoma, including updates from pivotal clinical studies, their utilization in neo-adjuvant and adjuvant treatment algorithms, as well as outcomes from novel combination strategies.

CME Information

page 1 of 6